Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.
November 21, 2018 at 05:00 am
Share
Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,200,000
PriceRange: KRW 17000
Discount Per Security: KRW 850
Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.
CYTOGEN, INC. 
